Endostatin

Mechanism of Action

• Binds alpha5beta1 and alphavbeta3 integrins on endothelial cells, blocking fibronectin and vitronectin-mediated adhesion and migration
• Inhibits VEGF signaling by competing for heparan sulfate proteoglycan binding sites
• Induces G1 cell cycle arrest in endothelial cells via cyclin D1 downregulation
• Promotes endothelial cell apoptosis by activating caspase-3/7 pathways
• Does not directly target tumor cells; effects are exclusively anti-angiogenic

Research Findings

• Folkman lab demonstrated endostatin could cause complete tumor regression and apparent cure in mice without resistance development
• Phase I/II clinical trials showed modest anti-tumor activity with acceptable toxicity in solid tumors
• Recombinant endostatin (Endostar, YH-16) approved in China for combination with chemotherapy in NSCLC
• Continuous low-dose infusion more effective than bolus dosing in preclinical models (metronomic concept)
• Endostatin combined with bevacizumab shows additive anti-angiogenic effects in colorectal cancer models

Research Protocols

• Endostar (China-approved): 7.5 mg/m2/day IV infusion over 3-4 hours for 14 days per cycle with chemotherapy
• Preclinical research dose: 2.5-20 mg/kg/day SC injection in mouse tumor models
• In vitro: 100-1000 ng/mL recombinant endostatin to assess endothelial migration inhibition
• Metronomic continuous IV at low dose (4-5 mg/kg) showed superior efficacy in some mouse models

Interactions

• Bevacizumab/VEGF inhibitors: additive anti-angiogenic effects
• Thrombospondin-1 and tumstatin: complementary inhibitory mechanisms
• Heparin: competes for HSPG binding, reducing endostatin activity; avoid co-administration

Safety Profile

Well tolerated in clinical trials. Mild fatigue, nausea, transient liver enzyme elevation reported. No significant hematologic toxicity. Approved for clinical use in China (Endostar). Investigational status elsewhere.

Legal & Regulatory

Approved in China (Endostar/YH-16); investigational in USA and EU